Pharmaceuticals

Pneumococcal Vaccine Market Expansion Forecast Reaching $66.3 Billion By 2030 At 10.9% CAGR

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Pneumococcal Vaccine Market During 2026–2030?

The pneumococcal vaccine market size has shown strong growth in recent years. It is anticipated to expand from $9.4 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth is attributable to several factors, including the significant burden of childhood pneumonia, the incorporation into national immunization programs, substantial backing from global health organizations, increasing awareness of invasive pneumococcal disease, and the demonstrated effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience substantial expansion over the coming years, reaching a valuation of $12.76 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by factors such as the introduction of next-generation PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare in developing nations, escalating concerns regarding antimicrobial resistance, and government financial support for preventive immunization initiatives. Key trends anticipated in this period include the broadening of conjugate vaccines to cover a greater range of serotypes, a heightened emphasis on immunization programs for children and the elderly, the increasing uptake of combination and booster vaccination methods, enhanced public-private collaborations to boost immunization coverage, and the overall rise in preventive healthcare practices and national immunization schedules.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Significant Factors Are Influencing The Pneumococcal Vaccine Market Expansion?

The rising occurrence of pneumococcal contamination is projected to boost the expansion of the pneumococcal vaccine market in the future. This contamination involves any infection stemming from bacteria known as Streptococcus pneumoniae or pneumococcus, encompassing conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine works by encouraging the body to generate antibodies against pneumococcal bacteria, aiming to diminish or eliminate disease-causing bacteria and toxins, thereby safeguarding children, older adults, and individuals with compromised immune systems from various forms of pneumococcal infections. A notable example comes from July 2025, where the Immunisation Coalition, an independent not-for-profit charity located in Australia, reported a consistent annual rise in invasive pneumococcal disease (IPD) cases, escalating from 1,869 in 2022 to 2,265 in 2023, and further to 2,379 in 2024. Consequently, the heightened prevalence of pneumococcal contamination serves as a key driver for the expansion of the pneumococcal vaccine market.

How Are Different Segments Classified In The Pneumococcal Vaccine Market Segment Analysis?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Emerging Trends Are Seen In The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are introducing new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals firm, unveiled the V116 vaccine. V116 is designed to target the eight specific serotypes of Streptococcus pneumoniae primarily causing adult pneumococcal disease. Exhibiting enhanced immunogenicity for various serotypes in adult populations compared to other pneumococcal vaccines, V116 has also generated positive immune responses in both individuals new to vaccination and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Who Are The Companies Driving Activity In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Get The Full Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Where Is The Pneumococcal Vaccine Market Primarily Concentrated By Region?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pneumococcal Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795